NCT02646371View on ClinicalTrials.gov

Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

July 31, 2017

Conditions
Shigellosis
Interventions
BIOLOGICAL

Flexyn2a

2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart

BIOLOGICAL

Placebo

2 doses of TBS solution will be injected intramuscularly 4 weeks apart

Trial Locations (1)

21205

Johns Hopkins Bloomberg School of Public Health, CIR, Baltimore

Sponsors
All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

LimmaTech Biologics AG

INDUSTRY

NCT02646371 - Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a | Biotech Hunter | Biotech Hunter